Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Shimozaki

Podiatrist Stockton, CA Doctor of Podiatric Medicine

NPI 1053429027 CMS profile 183565

3031 W March Ln, Suite 310, Stockton, CA 95219

Open in the dashboard

General payments

$4,257

206 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Shimozaki of Stockton, CA is reported in the CMS Open Payments database as having received $4,257 across 206 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $329 8
2024 General $675 24
2023 General $879 37
2022 General $828 39
2021 General $314 26
2020 General $424 35
2019 General $808 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Shimozaki
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Kenneth Shimozaki were reported at $329. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Kenneth Shimozaki Podiatrist median Middle half National median
2019 $808 $196 $72–$601 $163
2020 $424 $118 $38–$335 $114
2021 $314 $169 $57–$573 $132
2022 $828 $220 $74–$782 $149
2023 $879 $208 $71–$635 $160
2024 $675 $237 $87–$681 $164
2025 $329 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,229 89 payments
  2. TissueTech, Inc. $907 44 payments
  3. Organogenesis Inc. $584 31 payments
  4. Nevro Corp. $301 9 payments
  5. Celularity, Inc. $109 4 payments
  6. PolyNovo North America LLC $106 2 payments
  7. Averitas Pharma Inc. $95 1 payment
  8. Medline Industries, Inc. $92 2 payments
  9. MIMEDX Group, Inc. $91 1 payment
  10. Horizon Therapeutics plc $85 1 payment
  11. Other $657 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,257 206 payments
Products named General payments · program years 2019–2025
  1. Puraply $549 30 payments
  2. NEOX $371 23 payments
  3. CLARIX $371 23 payments
  4. COLLAGENASE SANTYL $268 19 payments
  5. Santyl $263 28 payments
  6. Senza $173 3 payments
  7. GRAFIX PL $170 6 payments
  8. GrafixPL $159 7 payments
  9. GRAFIX $159 7 payments
  10. Stravix $159 7 payments
  11. Other $2,424 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$709,368

Medicare's payments for the services billed

Medicare patients

238

Average age 77

Services billed

2,360

131 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 58%
Arthritis 50%
Chronic kidney disease 46%
Ischemic heart disease 36%
Heart failure 28%
Atrial fibrillation 27%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

206 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record